Napoleone Ferrara discusses Avastin and the future of anti-angiogenesis therapy. Interview by Ulrike Knies-Bamforth and Christopher Watson.
Ferrara
Napoleone
N
D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000235:genetics / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002626:Chemistry, Pharmaceutical / Q000379:methods / Q000639:trends; D006801:Humans; D051379:Mice; D042461:Vascular Endothelial Growth Factor A / Q000302:isolation & purification / Q000494:pharmacology / Q000627:therapeutic use
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab